Malignant tumors
Conditions
Interventions
Experimental group:None
Sponsors
Gongyi City People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Age >=18 years old, no gender limit; 2.Patients with malignant tumors confirmed by pathology or histology; 3.Volunteer to join this study and sign an informed consent form; 4.Patients who the researcher believes can benefit and receive treatment voluntarily.
Exclusion criteria
Exclusion criteria: 1.Patients have been confirmed to be allergic to drugs such as apatinib; 2. Patients with high blood pressure who cannot be reduced to the normal range by antihypertensive drugs (systolic blood pressure> 140 mmHg, diastolic blood pressure> 90 mmHg), coronary heart disease above grade I, grade I arrhythmia (including QTc interval prolongation) Male> 450 ms, female> 470 ms) and grade I cardiac insufficiency; 3.Urine routine shows urine protein >=++ or confirmed 24-hour urine protein quantitative >1.0g; 4.There are many factors that affect oral medications (such as inability to swallow, nausea, vomiting, chronic diarrhea and intestinal obstruction, etc.); 5.Patients with a clear gastrointestinal bleeding tendency, including the following conditions: local active ulcer lesions and fecal occult blood (++) cannot be included in the group; for fecal occult blood (++) and the primary tumor of the stomach, no surgery has been performed Resection requires gastroscopy, such as ulcerative gastric cancer, and the main investigator believes that hemorrhage of the digestive tract may occur; 6.Abnormal blood coagulation function (INR>1.5, APTT>1.5 ULN), with bleeding tendency; 7.Pregnant or lactating women; 8.Patients who have participated in other drug clinical trials within four weeks; 9.According to the judgment of the investigator, patients with concomitant diseases that seriously endanger the safety of the patient or affect the completion of the study; 10.The researcher believes that it is not suitable for inclusion.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| overall survival;objective remission rate;disease control rate; | — |
Primary
| Measure | Time frame |
|---|---|
| progression free survival; | — |
Countries
China
Contacts
Public ContactMeng Qiuli
Gongyi City People's Hospital
Outcome results
None listed